HC Wainwright Brokers Cut Earnings Estimates for Septerna

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Septerna in a research note issued on Tuesday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.48) per share for the year, down from their previous forecast of ($1.15). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Septerna’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Septerna’s Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.37) EPS and FY2027 earnings at ($1.34) EPS.

SEPN has been the topic of several other reports. Wells Fargo & Company increased their target price on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. JPMorgan Chase & Co. upped their target price on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a research note on Tuesday, August 11th. Finally, Stifel Nicolaus upped their target price on shares of Septerna from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.44.

Septerna Stock Performance

Shares of Septerna stock opened at $48.56 on Thursday. Septerna has a 52-week low of $18.64 and a 52-week high of $53.34. The stock has a market capitalization of $2.27 billion, a PE ratio of -37.64 and a beta of 2.20. The company has a 50-day simple moving average of $40.26 and a two-hundred day simple moving average of $32.95.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The company had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%.

Insiders Place Their Bets

In other news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares in the company, valued at $6,517,158.69. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Daniel D. Long sold 3,333 shares of Septerna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. The trade was a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. TRV GP V LLC purchased a new position in shares of Septerna in the second quarter valued at $208,160,143. TRV GP VI LLC bought a new position in Septerna during the second quarter valued at $141,048,460. BlackRock Inc. purchased a new position in shares of Septerna in the 2nd quarter worth $64,706,000. Jupiter Topco LLC purchased a new position in shares of Septerna in the 2nd quarter worth $43,723,000. Finally, Primecap Management Co. CA bought a new stake in shares of Septerna in the 2nd quarter worth about $39,096,000.

Septerna News Summary

Investors following SEPN have been watching these news items:

• Positive Sentiment: Stifel Nicolaus raised its price target to $60 from $49 and assigned a Buy rating, implying potential upside based on the quoted share price. Septerna Stock Gets Price Target Boost from Stifel Nicolaus
• Neutral Sentiment: An article highlighted a potential catalyst from a future SEP-479 readout, but the supplied headline does not provide details on timing or results. Septerna: The SEP-479 Readout Could Unlock Further Upside
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $1.48 from $1.15, and reduced forecasts for Q4 2026 and Q1 2027. These revisions point to larger expected near-term losses, partly offsetting its more optimistic 2027 outlook.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.